Drugs.com New Drug ApplicationsOriginal article
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
Phase 2positivezilurgisertibPositive
AI Analysis
Summary
Mirum Pharmaceuticals and Incyte announced positive pivotal Phase 2 results from the PROGRESS study evaluating zilurgisertib in Fibrodysplasia Ossificans Progressiva. The positive data represents a significant milestone for the investigational therapy.
Clinical Trial Data
Phase
Phase 2
Primary Endpoint
Met
Outcome Details
Pivotal Phase 2 results from Cohort 1 of the PROGRESS study announced
Importance:7/10
Sentiment:
0.85
Phase 2 DataPositive ResultsPartnershipFibrodysplasia Ossificans ProgressivaClinical Trial
Read the original article
Published by Drugs.com New Drug Applications on June 14, 2026 10:06 PM